Express Pharma

Dr Reddy’s Laboratories enters into licensing agreement with Slayback Pharma

The partnership aims to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify in the US

1 310

Dr Reddy’s Laboratories recently announced that it has entered into a licensing agreement with Slayback Pharma to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025 per cent, the private label equivalent of Lumify in the US. Lumify is an Over-The-Counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr Reddy’s exclusive rights to the product outside the US, the company said in a statement.

Slayback Pharma is the first company to file an ANDA for the private label equivalent for Lumify with the US Food and Drug Administration (FDA) under Paragraph IV certification. The ANDA is currently under FDA review and covers Brimonidine Tartrate Ophthalmic Solution 0.025 per cent in 2.5 ml and 7.5 ml fill volumes, it further added.

The value of total addressable market for this product in the US is approximately $130 million for the 52 weeks period ending 12th June, 2022, concluded the statement.